RNS Number : 0849B
Optos plc
11 August 2008
OPTOS PLC
("Optos" or the "Company" or the "Group")
APPOINTMENT OF JOINT BROKER
LONDON, UK, 11 August 2008 - Optos plc (LSE: OPTS), a leading medical technology company
for the design, development, manufacturing and
marketing of retinal imaging devices, is today pleased to announce the appointment of Piper
Jaffray Ltd as a joint broker to the Company
with immediate effect.
Enquiries
Maitland
Brian Hudspith
+44 (0) 207 379 5151
About Optos plc
Optos plc is a leading and rapidly growing medical technology company for the design,
development, manufacturing and marketing of
devices that image the retina, the light-sensitive area at the back of the eye. Both eye and
non-eye diseases often first exhibit in the
periphery of the retina. These are very difficult to detect clinically with conventional
examination equipment and techniques. Optos'
devices produce ultra wide-field, high resolution images of approximately 82% of the retina,
something no other device is capable of doing
in any one image. The images provide optometrists and ophthalmologists with enhanced clinical
information which facilitates the early
detection, management and treatment of disorders and diseases evidenced in the retina such as
retinal detachments and tears, glaucoma,
diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate
evidence of non-eye or systemic diseases such
as hypertension and certain cancers. Optos has a range of medical devices that support
different customer segments and patient levels: P200 device is concentrated on wellness
screening carried out by
optometrists and ophthalmologists in primary care; P200C device is designed to meet the need
for more exacting clinical imaging capabilities
and standards in secondary care within the ophthalmology market and at optometric practices
that are clinically managing a patient base with
advanced ocular disease; P200MA device supports retinal specialists, working primarily with a
diabetic patient base, in the medical care
market through an advanced medical angiography procedure. Optos' technology provides an
unequalled combination of wide-field retinal
imaging, speed and convenience for the practitioner and patient resulting in more targeted
treatment regimes and improved patient outcomes.This can help save sight and save lives. Optos estimates that it is addressing a market
opportunity with a combined $4 billion potential.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These
forward-looking statements are not historical facts
but rather are based on the Company's current expectations, estimates and projections about
its industry, its beliefs and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and
similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of future performance and are
subject to known and unknown risks,
uncertainties and other factors, some of which are beyond the Company's control, are difficult
to predict and could cause actual results to
differ materially from those expressed or forecasted in the forward-looking statements. The
Company cautions shareholders and prospective
shareholders not to place undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of
this announcement. The forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company will not undertake any
obligation to
release publicly any revisions or updates to these forward-looking statements to reflect
events, circumstances or unanticipated events
occurring after the date of this announcement except as required by law or by any appropriate
regulatory authority.
news service from the London Stock Exchange
END
MSCBXGDIXSBGGIB
|